Sandoz Group AG (SDZNY)
Sandoz Group AG operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Basel, ZG, CH. The stock last traded at $82.19, up 2.78% on the session, giving a market capitalisation of $35.56B. On trailing twelve-month figures it carries a trailing P/E of 54.86, a net margin of 5.6%. Its beta of 0.49 implies it has historically moved less than the broad market.
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Sandoz Group AG is most often compared with the following Healthcare names: